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and outcome of both surgical disciplines and the impact of numerous other fac-
tors. METHODS: Data were extracted from a major public health insurance claims 
database (~ 8 million clients) during a 3-year period (2010-2012). Patients aged 4-17 
years with appendectomy were included. Logistic regression analysis for risk of 
a surgical complication within the first 180-postoperative days was performed. 
Complications were defined by ICD and OPS codes. RESULTS: 8,110 patients were 
analyzed (PedSurg: n= 1,937; GenSurg: n= 6,173). Laparoscopic appendectomy was 
performed significantly more frequently by GenSurg compared to PedSurg (79% vs. 
61%). The complication rate during initial stay and the readmission rate for surgical 
complications were significantly higher in patients treated by PedSurg compared to 
those operated on by GenSurg (2.9% vs. 1.7% and 3.4% vs. 2.2% respectively, p< 0.01). 
Logistic regression analysis revealed no differences between the two surgical spe-
cialities for the risk of surgical complications during the initial hospital stay and 
no differences for the risk of readmission for a surgical complication in younger 
patients (4-11 years). In contrast, the risk of readmission for surgical complications 
in adolescents (12-17 years) was significantly higher if the patient was operated on 
by PedSurg (p< 0.01). The results showed that patients treated with laparoscopy had 
a significantly lower risk for developing surgical complications within the first 180 
postoperative days than patients who underwent an open surgery (OR: 0.73, p< 0.1). 
No differences were found for the variables geographical region and working day vs. 
weekendsurgery. CONCLUSIONS: With overall low complication and readmission 
rates after appendectomy this study revealed an excellent quality of care for appen-
dicitis in Germany. However, the increased risk of readmission for surgical compli-
cations in adolescent patients operated by PedSurg deserves future investigation.
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OBJECTIVES: A high prevalence of chronic kidney disease (CKD) in hepatitis C virus 
(HCV)-infected patients has been reported in Taiwan. By contrast, several studies 
in the United States (US) have not found an increased prevalence of CKD, suggest-
ing a possible geographic variation. We systematically reviewed the literature to 
determine the risk of developing of CKD in HCV-infected individuals. METHODS: 
MEDLINE and PUBMED were searched to identify observational studies that had 
reported an association between HCV and CKD or end-stage renal disease (ESRD) 
through 2014. Quantitative estimates (hazard ratio (HR) or odds ratio (OR)) and the 
95% confidence intervals (CI) were extracted from each study. Studies were system-
atically reviewed in accordance with PRISMA guidelines, and a random-effects meta-
analysis was performed. RESULTS: Eleven studies evaluating the risk of developing 
CKD/ESRD in HCV-infected individuals (n= 265714) compared to uninfected controls 
(n= 1674104) were identified- 7 cohort studies and 4 cross-sectional studies. The 
average years of follow-up ranged from 2.1 to 7.4 years. Five studies were from the 
US and 6 were from Taiwan. The pooled HR of CKD/ESRD in HCV+ individuals from 
the cohort studies was significant at 1.36 [95%CI:1.13-1.58] whereas the pooled OR 
from the cross-sectional studies was not- 1.16 [95%CI:0.92-1.40]. The overall pooled 
risk ratio from the 11 studies indicated that HCV+ individuals had a 30% greater 
risk of developing CKD/ESRD compared to uninfected individuals: risk ratio 1.29 
[95%CI:1.13-1.45]. Country-stratified analysis yielded a significantly increased risk 
between HCV and CKD in the Taiwanese subgroup (risk ratio= 1.24 [95%CI:1.05-1.48]) 
but not among the US subgroup (risk ratio= 1.23 [95%CI:0.92-1.54]). Egger regression 
revealed no evidence of publication bias. CONCLUSIONS: HCV infection is associ-
ated with a greater risk of developing CKD/ESRD compared to uninfected controls. 
This risk appears to be geographically linked with patients in Taiwan at higher risk 
for HCV related CKD/ESRD than those in the US.
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OBJECTIVES: To quantify liver transplant risk and mean total costs in treated versus 
untreated patients diagnosed with hepatitis C virus (HCV). METHODS: The sample 
included individuals with commercial or Medicare Advantage insurance, aged 19-89, 
with ≥ 1 HCV diagnosis or HCV treatment prescription claim between 1/1/2008 and 
6/30/2013, excluding those diagnosed with hepatitis B. Patients were observed during 
their full post-index enrollment following date of transplant or first HCV diagnosis or 
prescription. Cox proportional-hazard regression approximated adjusted relative risk 
(aRR) of transplant in treated versus untreated individuals, controlling for age, gender, 
geographic location, Deyo-Charlson Comorbidity Index, RxRisk-V Score, and pre-index 
medical and pharmacy costs. Results were also generated by treatment adherence 
level based on proportion of days covered (≥ 80%, 50-79%, < 50%). Mean total costs 
(plan- and patient-paid) were assessed over the observation period using generalized 
linear models with log link and gamma distribution. RESULTS: 93.7% (40,338/43,046) 
of the sample had no evidence of HCV treatment. Incidence of liver transplant was 
0.79% in untreated and 1.77% in treated individuals. There was no evidence that HCV 
treatment was associated with lower risk of transplant (aRR= 1.01, 95% confidence 
interval [CI] 0.80-1.50). Transplant risk in treated individuals did not vary by adherence 
(50-79% aRR= 0.86 [95% CI 0.19-2.72]; < 50% aRR= 1.73 [95% CI 0.73-4.38]; reference group 
≥ 80%). Transplant recipients incurred significantly higher mean total costs compared 
to those without transplant ($154,250 vs. $38,128, p< 0.0001). Among transplant recipi-
ents, costs were higher for treated versus untreated patients ($237,949 vs $141,616, 
p< 0.0001). CONCLUSIONS: Despite adjusting for covariates, there was no evidence 
that HCV treatment reduced risk of liver transplant, suggesting that treated patients 
may be sicker and have unmeasured confounders. However, within the treated group, 
there was no change in risk of transplant by level of adherence, underscoring the need 
for further evidence on liver transplant outcomes.
interval [CI], (-14.89 to -3.89 minutes) (P = 0.0008); intraoperative blood loss (WMD, 
-12.41 mL; 95% CI, -18.20 to -6.62 mL) (P < 0.0001); length of hospital stay (weighted 
mean difference [WMD], -1.23 days; 95% CI, (-1.68 to -0.78 days) (P < 0.00001); and 
recovery time of intestine function (weighted mean difference [WMD], -2.96 days; 
95% CI, (-5.20 to -0.72 days) (P = 0.01). There were also significant differences in intra-
operative complication rate (OR= 0.23, 95% CI (0.06,0.87), P= 0.03) and in postoperative 
complication rate (OR= 0.11, 95% CI (0.02,0.62), P= 0.01). CONCLUSIONS: This meta-
analysis clearly demonstrates that compared with electrocautery, ultrasonic scalpel 
can statistically significant reduce operation time, intraoperative blood loss, length 
of hospital stay, recovery time of intestine function, intraoperative complication rate 
and postoperative complication rate in LC in Chines population. It evidences that in 
China, ultrasonic scalpel offers a wide range of clinically relevant advantages and all 
of these advantages have clear economic impacts in laparoscopic cholecystectomy.
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OBJECTIVES: To describe current clinical characteristics and healthcare utiliza-
tion of CHC patients treated with newer DAA-based regimens using claims-linked 
lab data from a large US health plan. METHODS: The Optum Research Database 
(ORD) with medical and pharmacy claims-linked lab data for commercially-
insured patients and Medicare Advantage beneficiaries was used. Patients with 
CHC ≥ 18 years treated with simeprevir (SMV) and/or sofosbuvir (SOF) regimens 
after Nov2013 and with 6-months baseline health plan enrollment were followed 
from treatment initiation until Jun2014. ORD contained 123.1M cumulative lives 
as of Jun2014. RESULTS: 1,844 CHC patients were treated with SOF+RBV (33%) SOF 
+PEG+RBV (32%), SMV+SOF (29%) and SMV+SOF+RBV (6%) (n= 51 were treated with 
other regimens and excluded from analysis). Less than half of patients had a cir-
rhosis diagnosis (37%). 24% had claims-based evidence of end-stage liver disease. 
Over half (65%) were male; 68% white and 14% black; mean age was 57.5 years 
(SD= 9.5). One-third (33%) were Medicare beneficiaries; 67% were commercially 
insured. Mean treatment duration for completed regimens (n= 339) was 10.7 weeks; 
over half of regimens had treatment durations of > 11 to ≤ 15 weeks (57%). Among 
patients with genotype results available (n= 597), 1a (51%) was most common, fol-
lowed by 1b (18%) and 2 (17%). Approximately one-third of patients with liver func-
tion test results (n= 658) had baseline advanced liver fibrosis (29% with APRI > 1.5; 
33% with FIB-4 > 3.25). Significant variations in treatment regimen were seen across 
liver disease severity subgroups, including those with advanced liver fibrosis most 
often being treated with SMV+SOF and SOF+RBV. Healthcare resource utilization 
and cost per SVR will be examined when post-treatment outcomes data are avail-
able. CONCLUSIONS: The analysis provides current CHC treatment patterns in a 
large US payer database, evidence of potential variation in newer DAA treatment 
utilization by clinical characteristics, and suggests a significantly higher proportion 
of patients receiving SMV+SOF±RBV had advanced liver fibrosis.
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OBJECTIVES: Infliximab is associated with fewer Crohn’s disease (CD)-associated 
hospitalizations in randomized efficacy trials. Testing the effectiveness of inflixi-
mab using administrative data is challenging because many clinical predictors (i.e., 
degree of inflammation) are not available in coded data. We aimed to examine the 
effectiveness of infliximab on CD-related hospitalizations adjusting for confound-
ers using high-dimensional data mining. METHODS: A sample of CD cases was 
identified by at least two encounters for International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) code 555 from all active duty U.S. 
military personnel with service between 2001 and 2012. CD is an exclusion crite-
rion for enlistment resulting in an incident cohort. Outpatient Current Procedural 
Terminology (CPT) codes were used to identify early infliximab use (within 6 months 
of diagnosis). The outcome of interest was hospitalization after 6 months of diag-
nosis. We applied an algorithm to select confounding risk factors with a minimum 
prevalence of 0.04%. Univariable predictors with p< 0.05 were eligible for the final 
multivariable selection model (inclusion threshold p< 0.01). RESULTS: During a 
median of 2.04 years of follow-up, 10% of the 990 eligible patients used infliximab 
within 6 months of diagnosis, 30% were hospitalized within the first 6 months of 
diagnosis and 9% were hospitalized after 6 months. Early infliximab use was associ-
ated with an increased odds of hospitalization > 6 months (OR 0.76; 95% CI 0.26 – 
2.21) after adjustment for 64 model-selected factors including number of encounters 
(OR 0.98), abdominal pain (OR 5.39) and CT scan (OR 5.76). CONCLUSIONS: In this 
incident cohort of CD, early use of infliximab was not associated with a statistically 
significant decreased in hospitalizations, although the direction of effect was similar 
to trial results. These findings indicate that high dimensional data mining adjust-
ment is an option for modeling medication-outcome relationships.
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OBJECTIVES: In Germany children with appendicitis are treated by pediatric sur-
geons (PedSurg) as well as general surgeons (GenSurg). We analyzed the treatment 
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OBJECTIVES: There is a growing number of patients on the waiting list for liver 
transplantation, which is currently the only treatment option for patients with 
severe hepatic cirrhosis. The aim of this study was to determine the main factors 
and the impact of the cost of maintaining the cirrhotic patients on the waiting list 
for liver transplant. METHODS: We evaluated 493 patients on the waiting list for 
liver transplantation between the years 2012 and 2014. Of these 139 were called 
to transplantation, 190 remained on the waiting list, 106 were removed by health 
status and 58 died in the list. We used a detailed analysis of micro-costs on the 
waiting list, including clinical data and the cost of materials, drugs, laboratorial 
tests, human resources and hospitalizations. RESULTS: The total cost for patients 
with MELD> 30 was US$10,003.31 ± 7,277.82, MELD 15-29 US$6,585.66 ± 7,526.33 and 
MELD< 15 US$3,201.98 ± 5,001.30 (p < 0.001). The time spent in waiting list was 211 
± 228 days to MELD> 30, 308.17 ± 285.58 to MELD 15-30 and 209.1 ± 208.23 days to 
MELD< 15 (p< 0.001). Hospitalizations occurred in 69.9% of patients with MELD> 30, 
56.4% in MELD 15-30 and 25.8% in MELD< 15 (p< 0.05). The cost of hospitalizations 
was US$9,836.15 ± 7,024.82 in patients with MELD> 30, US$7,442.51 ± 7,792.56 for 
patients with MELD 15-30 and US$6,470.01 ± 6,927.64 to MELD< 15 (p< 0.05), cor-
responding to 68.1%, 60.9% and 51.1% of total expenditures respectively. The cost 
of medications and laboratorial tests for patients with MELD> 30 was US$3,826.31 
± 3,649.99, US$2,480.15 ± 2,996.56 to MELD 15-30 and US$1,271.28 ± 1,987.91 to 
MELD< 15 (p< 0.001). CONCLUSIONS: More severe patients have high-cost on wait-
ing list for liver transplantation. The long time on waiting list, complications that 
lead to hospitalizations, and expensive laboratorial tests and medications cause a 
great financial impact on the public health system.
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OBJECTIVES: New Hepatitis C (HCV) therapies are more effective at treating HCV, 
but come at higher financial costs. Boceprevir has been used with peginterferon 
and ribavirin antivirals for treatment of HCV, achieving sustained virologic response 
(SVR) rates of 65% in clinical trials. Simeprevir, sofosbuvir and combination ledipas-
vir and sofosbuvir are new therapies that have achieved SVR of over 90% in phase III 
clinical trials. Estimating the cost effectiveness of these new therapies is important 
for providers to determine which treatments to adopt in the context of growing cost 
concerns. METHODS: We used Markov simulation to evaluate the cost effectiveness 
of simeprevir, sofosbuvir and combination therapy ledipasvir and sofosbuvir vs. 
the assumed standard of care, boceprevir, among HCV genotype 1 patients over a 
30-year time horizon. Patients progress through stages of the natural history of HCV-
liver fibrosis/cirrhosis, liver transplant and death. Costs, QALYs and outcomes were 
estimated from clinical trials and previously published literature. We calculated 
the incremental net monetary benefit (INMB) between each therapy and standard 
of care. We ran multivariate probabilistic sensitivity analyses (PSA) to quantify the 
uncertainty of the results. RESULTS: New therapies have higher costs and yield 
higher QALYs than boceprevir. Simeprevir at 12 and 24 weeks have the highest INMB 
($85,335.02 and $19,069.64, respectively). Sofosbuvir/ribavirin has a net monetary 
loss compared to the standard of care. The results identify the simeprevir therapy 
to be the most cost effective. PSA reveals simeprevir has the highest likelihood of 
being cost-effective as compared to boceprevir when all inputs are varied simulta-
neously. CONCLUSIONS: Of the new HCV therapies, simeprevir therapy is the best 
value for money when compared to boceprevir. Simeprevir yields the highest QALYs 
of the newer therapy regimens. Further research should focus on patient adherence 
to therapy and associative costs of adverse events to better elucidate value.
PGI18
A cost-utIlIty AnAlysIs of bIoloGIcs for moderAte-to-seVere 
croHn’s dIseAse: eVIdence syntHesIs usInG A bAyesIAn network  
metA-AnAlysIs
Bounthavong M.1, Bae Y.H.2, Devine B.3, Veenstra D.L.3
1Univer, Seattle, WA, USA, 2Western University of Health Sciences, Pomona, CA, USA, 3University 
of Washington, Seattle, WA, USA
OBJECTIVES: To evaluate the cost-effectiveness of infliximab, adalimumab, certoli-
zumab pegol, and vedolizumab in Moderate-to-Severe Crohn’s disease from a US 
payer perspective with evidence synthesis from a Bayesian network meta-analysis 
(NMA). METHODS: A Markov model was constructed to evaluate the lifetime cost-
effectiveness of biologics and active control (azathioprine) in Crohn’s disease. The 
model used a 3-month cycle with six health states: Moderate-to-Severe, Mild-to-
Severe, Remission, Severe/Fulminant, Post-Surgery, and Death. Transition probabilities 
from Moderate-to-Severe to Remission were synthesized using a Bayesian NMA. Other 
transition probabilities and utility values were derived from the literature. Drug costs 
were based on Medicare Part-B Drug and Biological Average Sales Price Payment files. 
Costs and QALYs were discounted at 3-percent/year. One-way and probabilistic sensi-
tivity analyses (PSA) tested the robustness of the results. Willingness-to-pay threshold 
of $100,000/QALY was considered cost-effective. RESULTS: Transition probabilities 
(Moderate-to-Severe to Remission states) for active control, infliximab, adalimumab, 
certolizumab pegol, and vedolizumab were 0.240, 0.392, 0.483, 0.422, and 0.426, respec-
tively. Utility gained for active control, infliximab, adalimumab, certolizumab pegol, 
and vedolizumab were 17.84, 26.32, 26.35, 26.33, and 26.33 QALYs, respectively. Total 
direct costs for active control, infliximab, adalimumab, certolizumab pegol and vedoli-
zumab were $289,300, $330,700, $425,900, $547,800, and $423,200, respectively. ICER for 
infliximab compared to active control was $4,881/QALY gained. ICER for adalimumab 
GAstroIntestInAl dIsorders – cost studies
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OBJECTIVES: Rifaximin is a minimally absorbed antimicrobial agent that has demon-
strated efficacy for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in 
3 multicenter, randomized, controlled trials. After an initial 2-week course of therapy, 
rifaximin should be considered for repeat treatment only upon recurrence of symp-
toms, in contrast to other IBS treatment options that require chronic administration 
to maintain symptom improvement. The aim of this study was to evaluate the cost of 
adopting rifaximin for treating patients with IBS-D. METHODS: A model was created 
to project the incremental budget impact of adding rifaximin for treating patients 
with IBS-D in the US. The budget impact (2014 dollars) with rifaximin was estimated 
based on a hypothetical health plan with 10,000,000 members and 138,813 treated IBS 
patients receiving antidiarrheals, rifaximin, antispasmodics, alosetron, lubiprostone, 
linaclotide, and tricyclic antidepressants. Drug acquisition and office visit costs were 
applied to estimate the budget impact relative to the current environment over 3 years. 
Uptake of rifaximin was assumed to be 3.5% (year 1), 8.5% (year 2), and 15% (year 3). 
Adverse events and their associated costs were deemed similar between treatments 
and not included. RESULTS: The projected 1-, 2-, and 3-year budget impact of rifaximin 
resulted in annual savings for the health plan of $4,673,829 [per member per month 
(PMPM): $0.04], $11,350,728 (PMPM: $0.09), and $20,030,696 (PMPM: $0.17), totaling 
$36,055,253 over 3 years. Model results were most sensitive to time horizon, unit drug 
costs, and annual doses of alosetron and rifaximin; however, these only impacted the 
magnitude of savings relative to the current environment. Savings were expected when 
rifaximin was administered for up to 2 courses of therapy annually. CONCLUSIONS: 
This model suggests that the treatment of IBS-D with rifaximin, despite its higher unit 
cost, may be associated with savings when used up to twice per year.
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OBJECTIVES: The purpose of this study is to estimate the annual budget impact 
and the cost Per Member per Month of the testing and treatment of hepatitis C in 
the Medi-Cal population using the current testing guidelines METHODS: A budget 
impact analysis was constructed from a state Medicaid perspective to depict the 
financial consequences of implementing the testing and linkage to care guide-
lines recommended by the CDC, AASLD and USPSTF for persons born between 
1945 and 1965. The model included disease testing and drug reimbursement cost. 
Of the 2,277,106 Medi-Cal beneficiaries with birthdates between January 1, 1945 
and December 31, 1964, 1,894,144 are in the Fee for Service and not eligible for 
Medicare. Costs of adverse effects and non-adherence were excluded from the 
analysis. RESULTS: The total cost in one budgetary year of testing and treating the 
birth cohort ranged from between $5,230,285,333.21 and $24,207,966,240.39. The cost 
per member per month increases from $0.55 to between $77.76 and $357 if the birth 
cohort testing recommendation is implemented. CONCLUSIONS: In the base case 
analysis, the birth cohort testing increases the overall cost by over 100% from the 
current risk based testing and treating strategy. Furthermore, sensitivity analysis 
shows a 78% increase from the base case estimates if adjustments are made for 
additional risks in the birth cohort. Treatment of genotype 3 has the biggest budget 
impact followed by the treatment of Genotype1 Interferon ineligible persons. This 
research was conducted without the authorization of the California Department of 
Health Care Services and is not endorsed or validated by the Department.
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OBJECTIVES: The objective of the present study was to estimate the financial con-
sequences of using omeprazole immediate-release (IR) oral suspension versus 
intravenous (IV) infusion of pantoprazole for preventing stress-related upper gas-
trointestinal bleeding in critically ill patients from the perspective of the health care 
system. METHODS: An Excel®-based model was developed to compare the cost of 
prevention of upper gastrointestinal bleeding early after intensive care admission using 
the current IV pantoprazole formulation versus omeprazole IR oral suspension. Total 
costs included the cost of acid-suppressive drugs (proton pump inhibitors) and related 
clinical outcomes. Inputs were obtained from a local clinical trial, the Ministry of Health 
database, insurance organizations, hospital and pharmacy registries, the relevant litera-
ture, and expert opinion. The robustness of the input data was investigated by one-way 
sensitivity analysis. During the study period (November 2012 to September 2013), 4,150 
patients were admitted to intensive care units in the different provinces of Iran. The 
model was developed based on the results of a randomized controlled trial in which 
an experimental group and a control group received omeprazole IR oral suspension 
and pantoprazole IV, respectively. RESULTS: According to the proposed model, the cost 
of preventing gastrointestinal bleeding using pantoprazole IV was US$950,000, while 
US$750,000 was spent on omeprazole IR oral suspension. Replacement of IV pantopra-
zole by omeprazole IR oral suspension would lead to an annual cost saving of almost 
US$200,000 (US$4 per member per month) to the health care system. CONCLUSIONS: 
In the present study, a budget impact analysis was performed to assess the financial 
consequences of using omeprazole IR oral suspension in place of pantoprazole IV for 
prevention of upper gastrointestinal bleeding. The better preventive effect of omepra-
zole IR oral suspension when compared with conventional therapy using pantoprazole 
IV was the major reason for the final comparative budgetary savings.
